GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Earnings Yield (Joel Greenblatt) %

Immutep (Immutep) Earnings Yield (Joel Greenblatt) %

: 0.00% (As of Dec. 2023)
View and export this data going back to 1988. Start your Free Trial

Immutep's Enterprise Value for the quarter that ended in Dec. 2023 was $216.97 Mil. Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Immutep's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Immutep's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

IMMP' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -204.2   Med: -16.46   Max: -5.23
Current: -13.46

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Immutep was -5.23%. The lowest was -204.20%. And the median was -16.46%.

IMMP's Earnings Yield (Joel Greenblatt) % is ranked better than
54.29% of 1400 companies
in the Biotechnology industry
Industry Median: -15.465 vs IMMP: -13.46

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Immutep's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Immutep Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Immutep's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.21 -23.09 -8.44 -18.59 -15.85

Immutep Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -15.85 - -

Competitive Comparison

For the Biotechnology subindustry, Immutep's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Immutep's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Immutep's Earnings Yield (Joel Greenblatt) % falls into.



Immutep Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Immuteps Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-26.762/168.51541
=-15.88 %

Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.



Immutep  (NAS:IMMP) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Immutep Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Immutep's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (Immutep) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.